Russian government to provide compensations for domestic producers of cheap drugs

24 April 2015

The Russian government plans to provide compensations for the local drugmakers, specializing on the design and production of cheap and middle-priced drugs, which suffered through the current economic crisis in Russia, caused by Western sanctions, according to recent statements of Russia’s Prime Minister Dmitry Medvedev.

According to Mr Medvedev, the exact amount of compensations has not yet been defined. He added that the majority of producers hope for 80% indexation, however a final decision has not been taken. According to some sources in the Russian Ministry of Health, the amount of indexation will not exceed 30%, reports The Pharma Letter’s local correspondent.

According to state data, prices for drugs from cheap and middle-priced range since the beginning of the current year have increased by 20% but, according to data from some local analysts, these figures are significantly higher.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics